“Enhancing shareholder value through greater global visibility and attraction of foreign capital”
[by Ji, Yong Jun] ABL 바카라 용어, a company specializing in bispecific antibodies, announced on January 6 that it will conduct an overseas Non-Deal Roadshow (NDR) in the United States starting on January 19 (local time).
Through the NDR, ABL 바카라 용어 plans to engage with international institutional investors to present its bispecific antibody technology, the current status of its pipeline development, and future business strategies. Through these engagements, the company aims to strengthen credibility and trust among global investors and enhance shareholder value by promoting increased inflow of foreign capital.
ABL 바카라 용어 indicated that the roadshow will emphasize four core strategic areas: ABL001 (development code: tovecimig), Grabody-B, a blood-brain barrier (BBB) shuttle platform, Grabody-T, a 4-1BB-based bispecific antibody platform, and its portfolio of next-generation antibody-drug conjugates (ADCs).
ABL001 is a bispecific antibody targeting DLL4 and VEGF-A developed by ABL 바카라 용어 and subsequently licensed to the U.S.-based 바카라 용어pharmaceutical company Compass Therapeutics. The candidate is currently undergoing Phase 2/3 clinical trials as a second-line therapy for biliary tract cancer. Compass Therapeutics plans to disclose the complete Phase 2/3 clinical data in the first half of this year and, contingent upon the results, proceed with submission of a 바카라 용어logics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
Grabody-B is a proprietary shuttle platform designed to enhance drug delivery efficiency by targeting the insulin-like growth factor 1 receptor (IGF1R). In April 2025, ABL Bio entered into a licensing agreement valued at £2.14 billion (approximately KRW 4.1 trillion) with the global pharmaceutical company GlaxoSmithKline (GSK) for the Grabody-B platform.
In November of the same year, ABL 바카라 용어 further drew industry attention by entering into a technology transfer valued at USD 2.62 billion (approximately KRW 3.8 trillion) with Eli Lilly, alongside a strategic equity investment agreement totaling USD 15 million.
Grabody-T serves as a platform for the development of bispecific antibody immunotherapies designed to activate T cells within the tumor microenvironment in the presence of cancer cell-associated antigens. Among the Grabody-T-based pipeline, 바카라 용어111 (development code: givastomig), the most rapidly developing candidate, has demonstrated encouraging clinical activity in a Phase 1b trial in patients with metastatic gastric cancer when administered in combination with the PD-1 inhibitor nivolumab and chemotherapy (mFOLFOX6). Additionally, plans are in place to expand the clinical development of 바카라 용어503 (development code: ragistomig) as part of combination treatment strategies.
ABL Bio is also advancing the development of next-generation ADCs, including ‘dual antibody ADCs’ and ‘dual payload ADC platforms.’ Recently, the company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial of its dual-antibody ADC candidate, ‘ABL206’ (development code). In parallel, preparations are underway for the submission of a Phase 1 IND for ‘ABL209.’
"As our market capitalization has expanded following the technology transfer agreements with GSK and Eli Lilly, we have seen a notable increase in requests for NDRs from global asset managers and investment funds. By capitalizing on this momentum, we aim to attract greater participation from overseas passive funds and further enhance long-term shareholder value," said Lee Sang-hoon, CEO of ABL Bio.
"Following the U.S. NDR, we are also reviewing opportunities to conduct additional NDRs in key financial hubs such as Hong Kong and Singapore. We will continue to actively promote our technology and strive to evolve into a globally competitive biotechnology company," Lee further added.